medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2017, Número 1

<< Anterior Siguiente >>

Arch Neurocien 2017; 22 (1)


Uso de sertralina en el tratamiento de la fobia social-experiencia propia

Tomász RL

Idioma: Español
Referencias bibliográficas: 42
Paginas: 41-46
Archivo PDF: 178.28 Kb.


RESUMEN

El autor presenta el concepto general de la fobia y sus síntomas. Analiza el caso de uno de sus pacientes, al que trata de fobia social. Durante el proceso de educación se cometió una serie de errores. El paciente sometido a pruebas psiquiátricas personales y analizado con el uso de la Escala de Ansiedad Social de Liebowitz. Se realizaron varias pruebas adicionales. Se analizó el tratamiento del paciente con sertralina. El autor de este artículo trató a unos pacientes con fobia social con pregabalina.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.Aguglia E, Casacchia M, Cassano GB. University ofTrieste, Ttaly Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993; 8(3):197-202.

  2. 2.Bennie EH, Mullin JM, Martindale JJ. Levemdale Hospital, Glasgow, UK A double-blind multicenter trial comparing sertraline and fluoxetine in outpatiens with major depression. J Clin Psychiatry 1995; 56 (6): 229-37.

  3. 3.Beshay H, Pumarega AJ. Sertraline treatrn.ent of mood disorder associated with predmisone: a case report. J Child Adolescent Psychopharmacol 1998; 8(3):187-93.

  4. 4.Biri H, Isen K, Sinik Z. Sertraline in the treatment of prematute ejaculation: a double-blind placebo controlled study. lnt Urol Nephrol 1998; 30 (5): 611-5, 1998.

  5. 5.Brady KI, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatio stress disorder and alcohol dependence. J Clin Psychiatry 1995; 56 (11): 502-5.

  6. 6.Chouinard G. Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebocontrolled studies. Int Clin Psychopharmacol 1992; 7 Suppl 2: 37-41.

  7. 7.Croft H, Settle EJr, Houser T. A placebo-controlled comparison ofthe antidepressant efficacy and effects on sexual funcioning of sustained-release bupropion and sertraline. Clin Therapeutics 1999; 21(4): 643-58.

  8. 8.Davis SM, Harrison WM, Keller MB. The treatment of chronic depression, part 3: psychosocial functoning before and after treatment with sertraline or imiprarnine. J Clin Psychiatry 1998; 59 (11): 608-19.

  9. 9.Ekselius L, von Knorring L.Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram.Int Clin Pshychopharmacol 1998; 13(5) :205-11.

  10. 10.Finkel SL, Richter EM, Clary CM. Comperative efficiency and safety of sertraline versus nortriptyline in major depression in patiens 70 and older. Int Psychogeriatrics 1999; 11(1): 85-99.

  11. 11.Griest J, Chouinard B, DuBoffB. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch General Psycbiatry 1995; 52(4): 289-96.

  12. 12.Greist JH, Jefferson JW, Kobak KA. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsesive-compulsive disorder. International Clin Psychopharmacol 1995; 10 (2): 57-65.

  13. 13.Grignaschi G, Samanin R. Role of serotonin receptors in the effects of sertraline on feeding behaviour. Psychopharmacol 1993; 110(1-2): 203-8.

  14. 14.Hirschfeld RM, Russell JM, Delgado PL. Predictors of response to acute treatment of chronic and double depression with sertraline or impramine. J Clin Psychiatry 1998; 59 (12): 669-75.

  15. 15.Jermain DM, Preece CK, Syles RL. Luteat phase sertraline treatment for premenstrual dysphoric disorder. Results of a doubleblind, placebo-controlled, crossover study. Arch Family Medicine 1999; 8 (4): 328-32.

  16. 16.Kant R, Smith-Seerniller L, Zeiler D. Treatment of agression and irritability after head injury. Brain lnjury;1988; 12 (8): 661-6.

  17. 17.Katzelnick DJ, Kobak KA, Greist JH. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Ame J Psychiatry 1995; 152(9): 1368-71.

  18. 18.Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disorder patients with impulsive agression. J Clin Psychiatry 1994; 55 (4): 137-41.

  19. 19.Keller MB, Gelenberg AJ, Hirschfeld RM. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998; 59 (11): 598-607.

  20. 20.Keller MB, Harrsion W, Fawcett JA. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates ofundertreatment in the community. Psychophannacol Bull 1995; 31(2): 205-12.

  21. 21.Keller MB, Kocsis JH, Thase M. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 1998; 280(19): 1665-72.

  22. 22.Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophrenia Res 1998; 33:1-2.

  23. 23.Kroning MH, Apter J, Asnis G. Placebo-controlled, multicenter dudy of sertraline treatment for obsessivecompulsive disorder. J Clin Psychopharmacol 1999; 19 (2):172-6.

  24. 24.Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Progress Neuro- Psychophannacol Biol Psychiatry 1998; 22 (5): 741-8.

  25. 25.Lauterbach EC. Catatonia - like events after valproic acid with reisperidone and sertraline. Neuropsych, Neuropsychol Behavioral Neurol 1998; 11(3): 157-63.

  26. 26.Levin ID, Briggs SJ, Christopher NC. Sertraline attenuates hyperphagia in rats following nicotine withdrawal. Phannacol, Biochem Behavior 1993;44 (1): 51-61.

  27. 27.Londborg PD, Wolkow R, Srnith WT. Sertraline in the treatment of panic disorder. A multi-site, doubleblind, placebo-controlled, fixed-dose investigation. Brit J Psychiatry 1998; 173: 54-60.

  28. 28.Luketsos GB, Taragano F, Freisman GJ. Major depression and its rsponce to sertraline in primary care vs. psychiatric office practice patients, results of an open-label trial in Argentina. Psychosomatics 1999; 40(1):70-5.

  29. 29.McMahon DG. St. Treatment of premature ejaculation with sertraline hydrochloride. International J Impotence Research 1998; 10(3):181-4.

  30. 30.Molier HJ, Gallinat J, Hegerl U. Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Pharmacopsychiatry 1998; 31(6):170-7.

  31. 31.Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsesive compulsice disorder.Sertralina. Drugs 1992; 44 (4): 604-24.

  32. 32.Oinan TG. Lithiurn augmentation in sertraline- resistant depression: a preliminary dose- response study. Psychiatrica Scandinavica 1993; 88 (4): 300-1.

  33. Pollack MH, Otto MW, Wortington JJ. Sertratine in the treatment ofpanic disorder: a flexible-dose multicenter trial. Arch General Psychiatry 1998; 55(11):1010-6. 34.Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Internat Clin Psychopharmacol 1996; 10 (3):129-41.

  34. 35.RoyA. Placebo - controlled study of sertraline in depressed recently abstinent alcoholics. Biological Psychiatry; 1998; 44 (7): 633-6.

  35. 36.Rush AJ, Koran LM, Keller MB. The treatment of chronic depression, part 1: Study design and rationale for evaluating the comparative efficacy of sertraline and irnipramine as acute, crossover, continuation and maintenace phase therapies. J Clin Psychiatry 1998; 59 (11): 589-97.

  36. 37.Shapiro PA, Lesperance F, Frasure-Smith N. An open-label preliminary trial of sertraline for treatmnt of major depression after acute myocardial infarction. Am Heart J 1999; 137(6):1100-6.

  37. 38.TurnerR. Quality oflife: experience with sertraline. Internat Clin Psychopharmacol 1994; 9 Suppl 3: 27-31.

  38. 39.TurnerR. Sertraline in social phobia. Anxiety 1994; (4):196-8.

  39. 40.Wadden TA, Bartlett SJ, Foster GD. Sertraline and relapse prevention training following treatment by verylow- calorie diet: a controlled clinical tria!. Obsesity Research 1995; 3(6): 549-57.

  40. 41.Frampton JE. Pregabalin; review of its use in adults with generalized anxiety disorder.CNS Drugs 2014; 28: 835-54.

  41. 42.Both C, Kojda C, Lange Asschenfeldt C.Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin. Exp Rev Neurotherap 2014; 14:29-38.

  42. 43.Olivares JM, Alvarez E, Carrasco JL, Perez Paramo P, Lopez-Gomez V. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms.In Clin Psychopharmacol 2015; 30: 265-27.




2020     |     www.medigraphic.com